OPERATING_VBG
ACTIVITIES_NOMZ
MARKETING_VBG [WZPRES]
AND_CC
DISTRIBUTION_NOMZ
Smith_NN
&_CC
Nephews_NN
customers_NN
are_VPRT [BEMA]
the_DT
various_JJ
providers_NN
of_PIN
medical_JJ
and_PHC
surgical_JJ
services_NN
worldwide_NN
._.
In_PIN
certain_JJ
parts_NN
of_PIN
the_DT
world_NN
,_,
including_VBG [PRESP]
the_DT
UK_NN
,_,
much_QUAN
of_PIN
Continental_NN
Europe_NN
,_,
Australia_NN
,_,
Canada_NN
and_PHC
South_NN
Africa_NN
,_,
these_DEMP
are_VPRT [BEMA]
largely_RB
governmental_JJ
organizations_NOMZ
funded_VBN [WZPAST]
by_PIN
tax_NN
revenues_NN
._.
In_PIN
the_DT
US_FPP1
,_,
the_DT
Groups_NN
major_JJ
customers_NN
are_VPRT [BEMA]
public_PRED
and_PHC
private_PRED
hospitals_NN
,_,
many_QUAN
of_PIN
which_WDT [PIRE]
have_VPRT [PEAS]
combined_VBN
to_TO
form_VB
large_JJ
purchasing_GER
groups_NN
and_CC
receive_VB
revenue_NN
from_PIN
private_JJ
health_NN
insurance_NN
and_CC
governmental_JJ
reimbursement_NOMZ
programs_NN
._.
In_PIN
the_DT
US_FPP1
,_,
Medicare_NN
is_VPRT [BEMA]
the_DT
major_JJ
source_NN
of_PIN
reimbursement_NOMZ
for_PIN
knee_NN
and_CC
and_CC
for_PIN
regimes_NN
._.
Competition_NOMZ
exists_VPRT
among_PIN
healthcare_NN
providers_NN
to_TO
gain_VB
patients_NN
on_PIN
the_DT
basis_NN
of_PIN
quality_NOMZ
,_,
service_NN
and_PHC
price_NN
._.
In_PIN
many_QUAN
countries_NN
,_,
providers_NN
are_VPRT
under_IN
pressure_NN
to_TO
reduce_VB
the_DT
total_JJ
cost_NN
of_PIN
healthcare_NN
delivery_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
some_QUAN
consolidation_NOMZ
in_PIN
the_DT
Groups_NN
customer_NN
base_NN
,_,
as_RB
well_RB
as_IN
amongst_PIN
the_DT
Groups_NN
competitors_NN
,_,
and_ANDC
these_DEMO
trends_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
continue_VB
in_PIN
the_DT
long_JJ
term_NN
._.
Smith_NN
&_CC
Nephew_NN
competes_VPRT
against_PIN
both_DT
specialised_VBN
and_CC
multinational_JJ
corporations_NOMZ
,_,
includingthose_JJ
withgreater_NN
financial_JJ
,_,
marketingand_JJ
other_JJ
resources_NN
._.
The_DT
Groups_NN
customers_NN
reflect_VPRT [PRIV]
the_DT
wide_JJ
range_NN
of_PIN
distribution_NOMZ
channels_NN
,_,
purchasing_VBG
agents_NN
and_CC
buying_VBG
entities_NOMZ
in_PIN
over_IN
90_CD
countries_NN
worldwide_JJ
._.
The_DT
largest_JJ
single_JJ
customers_NN
worldwide_NN
are_VPRT [BEMA]
the_DT
National_NN
Health_NN
Service_NN
in_PIN
the_DT
UK_NN
and_PHC
HealthTrust_NN
in_PIN
the_DT
US_FPP1
._.
Sales_NN
to_PIN
these_DEMO
customers_NN
in_PIN
2005_CD
represented_VBD
approximately_RB
5_CD
%_NN
and_CC
4_CD
%_NN
of_PIN
the_DT
Groups_NN
worldwiderevenue_VPRT
respectively_RB
._.
In_PIN
the_DT
US_FPP1
the_DT
Groups_NN
products_NN
are_VPRT [PASS]
marketed_VBN
directly_RB
to_PIN
doctors_NN
,_,
hospitals_NN
and_CC
other_JJ
healthcare_NN
facilities_NOMZ
._.
Each_QUAN
business_NOMZ
unit_NN
operates_VPRT
a_DT
separate_JJ
specialised_JJ
sales_NN
force_NN
._.
Within_PIN
the_DT
orthopaedics_NN
business_NOMZ
further_JJ
specialisation_NOMZ
of_PIN
the_DT
sales_NN
force_NN
continues_VPRT
to_TO
be_VB [PASS]
introduced_VBN
progressively_RB
for_PIN
reconstruction_NOMZ
,_,
trauma_NN
and_CC
clinical_JJ
therapy_NN
products_NN
._.
In_PIN
both_DT
orthopaedics_NN
reconstruction_NOMZ
and_CC
endoscopy_JJ
the_DT
US_FPP1
sales_NN
forces_NN
consist_VPRT
largely_RB
of_PIN
independent_JJ
commissioned_VBN
sales_NN
agents_NN
who_WP [WHSUB]
are_VPRT [BYPA]
managed_VBN
by_PIN
a_DT
mix_NN
of_PIN
independent_JJ
agents_NN
and_CC
the_DT
Groups_NN
own_VPRT
managers_NN
._.
These_DEMO
agents_NN
are_VPRT [PASS]
not_XX0
permitted_VBN
contractually_RB
to_TO
sell_VB
products_NN
that_TSUB
compete_VPRT
with_PIN
Smith_NN
&_CC
Nephews_NN
._.
In_PIN
both_DT
businesses_NOMZ
,_,
products_NN
are_VPRT [PASS]
shipped_VBN
and_PHC
invoiced_VBN
directly_RB
to_PIN
the_DT
ultimate_JJ
customer_NN
._.
The_DT
trauma_NN
and_CC
clinical_JJ
therapies_NN
and_CC
advanced_JJ
wound_NN
management_NOMZ
businesses_NOMZ
in_PIN
the_DT
US_FPP1
operate_VPRT
sales_NN
forces_NN
of_PIN
their_TPP3
own_JJ
employees_NN
who_WP [WHSUB]
market_VPRT
directly_RB
to_PIN
the_DT
ultimate_JJ
customer_NN
._.
In_PIN
the_DT
US_FPP1
,_,
trauma_NN
and_CC
clinical_JJ
therapy_NN
products_NN
are_VPRT [PASS]
shipped_VBN
and_PHC
invoiced_VBN
directly_RB
to_PIN
the_DT
ultimate_JJ
customer_NN
whereas_OSUB
advanced_JJ
wound_NN
management_NOMZ
products_NN
are_VPRT [PASS]
shipped_VBN
and_PHC
invoicedto_VB
a_DT
numberof_JJ
large_JJ
wholesale_JJ
distributors_NN
._.
In_PIN
the_DT
other_JJ
direct_JJ
markets_NN
of_PIN
the_DT
UK_NN
,_,
Ireland_NN
,_,
France_NN
,_,
Germany_NN
,_,
Italy_NN
,_,
Australia_NN
,_,
New_NN
Zealand_NN
,_,
Canada_NN
and_PHC
Japan_NN
the_DT
business_NOMZ
units_NN
manage_VPRT
separate_JJ
sales_NN
forces_NN
directly_RB
._.
Except_PIN
in_PIN
Australia_NN
and_PHC
New_NN
Zealand_NN
where_RB
independent_JJ
sales_NN
agents_NN
are_VPRT [PASS]
used_VBN
the_DT
sales_NN
forces_NN
of_PIN
the_DT
direct_JJ
markets_NN
comprise_VPRT
employees_NN
and_PHC
market_NN
directly_RB
to_PIN
the_DT
ultimate_JJ
customer_NN
._.
The_DT
indirect_JJ
markets_NN
unit_NN
comprises_VPRT
direct_JJ
selling_GER
and_PHC
marketingoperations_NOMZ
inAustria_NN
,_,
Belgium_NN
,_,
Denmark_NN
,_,
Eastern_NN
Europe_NN
,_,
Finland_NN
,_,
the_DT
Netherlands_NN
,_,
Norway_NN
,_,
Poland_NN
,_,
Portugal_NN
,_,
Spain_NN
,_,
Sweden_NN
,_,
Switzerland_NN
,_,
China_NN
,_,
Hong_NN
Kong_NN
,_,
Korea_NN
,_,
Malaysia_NN
,_,
Singapore_NN
,_,
Taiwan_NN
,_,
Thailand_NN
,_,
the_DT
United_NN
Arab_NN
Emirates_NN
,_,
South_NN
Africa_NN
,_,
Mexico_NN
and_PHC
Puerto_NN
Rico_NN
._.
In_PIN
these_DEMO
markets_NN
orthopaedics_NN
and_CC
endoscopy_JJ
frequently_RB
share_NN
sales_NN
resources_NN
._.
The_DT
advanced_JJ
wound_NN
management_NOMZ
sales_NN
force_NN
is_VPRT [BEMA]
separate_PRED
since_OSUB
it_PIT
calls_VPRT
on_PIN
different_JJ
customers_NN
._.
In_PIN
all_QUAN
other_JJ
countries_NN
Smith_NN
&_CC
Nephew_NN
sells_VPRT
to_PIN
third_JJ
party_NN
distributors_NN
whichmarket_VPRT
the_DT
Groups_NN
products_NN
locally_PLACE
._.
In_PIN
Continental_NN
Europe_NN
,_,
the_DT
Group_NN
operates_VPRT
three_CD
centralised_JJ
distribution_NOMZ
facilities_NOMZ
._.
Orthopaedics_NN
operates_VPRT
a_DT
facility_NOMZ
in_PIN
Paris_NN
which_WDT [WHSUB]
acts_VPRT
as_IN
a_DT
central_JJ
holding_GER
and_PHC
consolidation_NOMZ
point_NN
for_PIN
Continental_JJ
European_JJ
stock_NN
and_PHC
stock_NN
returns_NN
._.
Product_NN
is_VPRT [PASS]
shipped_VBN
to_PIN
Group_NN
companies_NN
who_WP [WHSUB]
hold_VPRT [PRIV]
small_JJ
amounts_NN
of_PIN
stock_NN
locally_PLACE
for_PIN
immediate_JJ
or_CC
urgent_JJ
customer_NN
requirements_NOMZ
._.
Advanced_NN
wound_VBD
management_NOMZ
operates_VPRT
distribution_NOMZ
centres_NN
at_PIN
Nijmegen_NN
,_,
Netherlands_NN
and_PHC
Gothenburg_NN
,_,
Sweden_NN
from_PIN
where_RB
stock_NN
is_VPRT [PASS]
shipped_VBN
directly_RB
to_PIN
the_DT
ultimate_JJ
customer_NN
in_PIN
most_EMPH
European_JJ
markets_NN
._.
MANUFACTURE_NN
AND_PHC
SUPPLY_NN
Where_RB
management_NOMZ
considers_VPRT [PRIV]
that_THVC
the_DT
Group_NN
possesses_VPRT
a_DT
core_NN
competence_NN
its_PIT
policy_NN
is_VPRT
to_TO
manufacture_VB
products_NN
internally_RB
whenever_RB
possible_JJ
to_TO
ensure_VB [SUAV] [PRIV]
quality_NOMZ
,_,
regulatory_JJ
and_CC
cost_NN
goals_NN
are_VPRT [PASS]
met_VBN
._.
The_DT
Group_NN
invests_VPRT
in_PIN
the_DT
expansion_NN
of_PIN
its_PIT
manufacturing_GER
facilities_NOMZ
and_PHC
equipment_NOMZ
to_TO
meet_VB
these_DEMO
aims_NN
._.
The_DT
Group_NN
may_POMD
outsource_VB
some_QUAN
manufacturing_GER
for_PIN
several_QUAN
reasons_NN
including_VBG [WZPRES]
requirements_NOMZ
for_PIN
specialised_JJ
expertise_NN
,_,
where_RB
appropriate_JJ
to_TO
achieve_VB
lowercosts_NN
of_PIN
productionand_NN
due_JJ
to_PIN
capacity_NOMZ
constraints_NN
._.
13_CD
Where_RB
products_NN
and_PHC
services_NN
are_VPRT [PASS]
outsourced_VBN
,_,
suppliers_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
a_DT
number_NN
of_PIN
factors_NN
which_WDT [WHSUB]
include_VPRT
the_DT
complexity_NOMZ
of_PIN
the_DT
product_NN
,_,
manufacturing_VBG
technology_NN
,_,
manufacturing_VBG
capabilities_NOMZ
,_,
cost_NN
competitiveness_NOMZ
and_CC
intellectual_JJ
property_NN
._.
Suppliers_NN
are_VPRT [PASS]
selected_VBN
based_VBN
on_PIN
their_TPP3
capability_NOMZ
to_TO
provide_VB
products_NN
and_PHC
services_NN
,_,
their_TPP3
ability_NOMZ
to_TO
establish_VB [PRIV]
and_PHC
maintain_VB [PUBV]
a_DT
quality_NOMZ
system_NN
and_CC
their_TPP3
financial_JJ
stability_NOMZ
._.
Suppliers_NN
are_VPRT [BYPA]
monitored_VBN
by_PIN
on-site_JJ
assessments_NOMZ
and_CC
on-going_JJ
monitoring_GER
of_PIN
delivered_VBN
products_NN
._.
Ongoing_JJ
product_NN
assurance_NN
is_VPRT [BEMA]
maintainedby_JJ
effective_JJ
quality_NOMZ
plans_NN
._.
Each_QUAN
business_NOMZ
unit_NN
purchases_NN
raw_JJ
materials_NN
,_,
components_NN
,_,
finished_VBD
products_NN
and_PHC
packaging_GER
materials_NN
from_PIN
certain_JJ
key_JJ
suppliers_NN
._.
These_DEMP
comprise_VPRT
principally_RB
metal_NN
forgings_GER
and_PHC
stampings_GER
for_PIN
orthopaedics_NN
,_,
optical_JJ
and_PHC
electronic_JJ
sub-components_NN
and_CC
finished_VBN
goods_NN
for_PIN
endoscopy_JJ
,_,
active_JJ
ingredients_NN
and_CC
finished_VBN
goods_NN
for_PIN
advanced_JJ
wound_NN
management_NOMZ
and_PHC
packaging_GER
materials_NN
for_PIN
all_QUAN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
whilst_OSUB
prices_NN
of_PIN
principal_JJ
raw_JJ
materials_NN
can_POMD
be_VB [BEMA]
volatile_PRED
the_DT
effect_NN
is_VPRT [BEMA]
not_XX0
material_PRED
to_PIN
the_DT
Group_NN
._.
Finished_VBN
goods_NN
purchased_VBD
for_PIN
resale_NN
are_VPRT
primarily_RB
SUPARTZ_NN
joint_JJ
lubricant_NN
and_CC
the_DT
BHR_NN
hip_NN
resurfacing_VBG [WZPRES]
product_NN
in_PIN
the_DT
orthopaedic_JJ
business_NOMZ
,_,
screen_NN
displays_NN
and_CC
electrical_JJ
devices_NN
in_PIN
the_DT
endoscopy_JJ
business_NOMZ
and_PHC
enzyme_NN
debrider_NN
agents_NN
and_PHC
ACTICOAT_NN
in_PIN
the_DT
advanced_JJ
woundmanagement_NOMZ
business_NOMZ
._.
SEASONALITY_NOMZ
Smith_NN
&_CC
Nephews_NN
revenues_NN
are_VPRT [BEMA]
generally_RB
at_PIN
their_TPP3
highest_JJ
in_PIN
quarter_NN
four_CD
of_PIN
any_QUAN
year_NN
._.
This_DEMP
is_VPRT [BYPA]
caused_VBN
by_PIN
the_DT
relatively_RB
high_JJ
number_NN
of_PIN
accidents_NN
and_PHC
sports_NN
injuries_NN
which_WDT [WHSUB]
occur_VPRT
in_PIN
the_DT
North_PLACE
American_JJ
and_PHC
European_JJ
autumn_NN
and_PHC
winter_NN
seasons_NN
which_WDT [WHSUB]
increase_VPRT
revenues_NN
of_PIN
orthopaedic_JJ
and_PHC
endoscopy_JJ
products_NN
and_CC
by_PIN
the_DT
higher_JJ
rates_NN
of_PIN
elective_JJ
surgery_NN
inthe_JJ
quarter_NN
._.
RESEARCH_NN
AND_PHC
DEVELOPMENT_NOMZ
The_DT
business_NOMZ
units_NN
each_QUAN
manage_VPRT
a_DT
portfolio_NN
of_PIN
short_JJ
and_PHC
long-term_JJ
product_NN
development_NOMZ
projects_NN
designed_VBN
to_TO
meet_VB
the_DT
future_JJ
needs_NN
of_PIN
their_TPP3
customers_NN
and_CC
to_TO
continue_VB
to_TO
provide_VB
growth_NN
opportunities_NOMZ
for_PIN
their_TPP3
businesses_NOMZ
._.
The_DT
Groups_NN
research_NN
and_PHC
development_NOMZ
is_VPRT [PASS]
directed_VBN
towards_PIN
all_QUAN
three_CD
business_NOMZ
segments_NOMZ
._.
Expenditure_NN
on_PIN
research_NN
and_PHC
development_NOMZ
amounted_VBD
to_TO
67m_VB
in_PIN
2005_CD
2004_CD
66m_NN
,_,
2003_CD
67m_CD
,_,
representing_VBG [PRESP]
approximately_RB
5_CD
%_NN
of_PIN
groupturnover_NN
2004_CD
5_CD
%_NN
,_,
2003_CD
6_CD
%_NN
._.
The_DT
Groups_NN
principal_JJ
research_NN
facility_NOMZ
is_VPRT [PASS]
located_VBN
in_PIN
York_NN
,_,
England_NN
._.
The_DT
Groups_NN
research_NN
program_NN
seeks_VPRT
to_TO
underpin_VB
the_DT
longer-term_JJ
technology_NN
requirements_NOMZ
for_PIN
its_PIT
businesses_NOMZ
and_CC
to_TO
provide_VB
a_DT
flow_NN
of_PIN
innovative_JJ
products_NN
._.
The_DT
Group_NN
continues_VPRT
to_TO
invest_VB
in_PIN
future_JJ
technology_NN
opportunities_NOMZ
,_,
particularly_RB
bio-resorbable_JJ
materials_NN
,_,
tissue_NN
engineering_GER
and_CC
non-invasive_JJ
healing_GER
devices_NN
across_PLACE
the_DT
Group_NN
._.
In-house_JJ
research_NN
is_VPRT [BYPA]
supplemented_VBN
by_PIN
work_NN
._.
Product_NN
development_NOMZ
is_VPRT [PASS]
carried_VBN
out_PIN
at_PIN
the_DT
Groups_NN
principal_JJ
locations_NOMZ
,_,
notably_RB
in_PIN
Memphis_NN
,_,
Tennessee_NN
orthopaedics_NN
,_,
Andover_NN
and_PHC
Mansfield_NN
,_,
Massachusetts_NN
endoscopy_JJ
and_CC
Hull_NN
,_,
England_NN
advanced_VBD
wound_NN
management_NOMZ
._.
INTELLECTUAL_JJ
PROPERTY_NN
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
the_DT
Groups_NN
policy_NN
concerning_VBG [WZPRES]
intellectual_JJ
property_NN
rights_NN
promotes_VPRT
innovation_NOMZ
in_PIN
its_PIT
businesses_NOMZ
._.
Smith_NN
&_CC
Nephew_NN
has_VPRT
a_DT
policy_NN
of_PIN
protecting_VBG
,_,
with_PIN
patents_NN
,_,
the_DT
results_NN
of_PIN
the_DT
research_NN
and_PHC
development_NOMZ
carried_VBD
out_PIN
by_PIN
the_DT
Group_NN
._.
Patents_NN
have_VPRT [PEAS]
been_VBN [PASS]
obtained_VBN
for_PIN
a_DT
wide_JJ
range_NN
of_PIN
products_NN
,_,
including_VBG [PRESP]
those_DEMO
in_PIN
the_DT
fields_NN
of_PIN
orthopaedic_JJ
,_,
endoscopic_JJ
and_PHC
advanced_JJ
wound_NN
management_NOMZ
technologies_NN
._.
Patent_NN
protection_NOMZ
for_PIN
Group_NN
products_NN
is_VPRT [PASS]
sought_VBN
routinely_RB
in_PIN
the_DT
Groups_NN
principal_JJ
markets_NN
._.
Currently_RB
,_,
the_DT
Groups_NN
patent_NN
portfolio_NN
stands_VPRT
at_PIN
over_IN
2,300_CD
existing_VBG
patents_NN
and_PHC
patent_NN
applications_NOMZ
._.
Smith_NN
&_CC
Nephew_NN
also_RB
has_VPRT
a_DT
policy_NN
of_PIN
protecting_VBG
the_DT
Groups_NN
products_NN
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
sold_VBN
by_PIN
registering_VBG
trademarks_NN
as_OSUB
soon_NULL
as_NULL
possible_JJ
under_IN
local_JJ
laws_NN
._.
The_DT
Group_NN
vigorously_RB
protects_VPRT
its_PIT
trademarks_NN
against_PIN
infringement_NOMZ
and_CC
currently_RB
is_VPRT [BEMA]
not_XX0
aware_PRED
of_PIN
any_QUAN
significant_JJ
infringement_NOMZ
of_PIN
its_PIT
trademark_NN
registrations_NOMZ
._.
The_DT
present_JJ
trademark_NN
portfolioof_NN
the_DT
Group_NN
consists_VPRT
of_PIN
over_IN
3,300_CD
trademarks_NN
and_PHC
design_NN
rights_NN
._.
Smith_NN
&_CC
Nephews_NN
principal_JJ
products_NN
are_VPRT [BYPA]
protected_VBN
by_PIN
intellectual_JJ
property_NN
comprising_VBG [WZPRES]
patents_NN
,_,
licences_NN
and_ANDC
know-how_NN
,_,
and_ANDC
it_PIT
strives_VPRT
to_TO
provide_VB
a_DT
collection_NOMZ
of_PIN
intellectual_JJ
property_NN
for_PIN
each_QUAN
major_JJ
product_NN
that_TSUB
reduces_VPRT
the_DT
risk_NN
associated_VBN [WZPAST]
with_PIN
failure_NN
of_PIN
any_QUAN
individual_JJ
piece_NN
of_PIN
intellectual_JJ
property_NN
._.
In_CONJ
addition_NULL
,_,
most_EMPH
pieces_NN
of_PIN
intellectual_JJ
property_NN
protect_VPRT
a_DT
relatively_RB
small_JJ
proportion_NOMZ
of_PIN
the_DT
Groups_NN
annual_JJ
revenue_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
Group_NN
tries_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
its_PIT
overall_JJ
business_NOMZ
is_VPRT [BEMA]
not_XX0
sensitive_PRED
to_PIN
the_DT
loss_NN
however_CONJ
caused_VBD
of_PIN
any_QUAN
single_JJ
piece_NN
of_PIN
intellectual_JJ
property_NN
._.
14_CD
In_CONJ
addition_NULL
to_TO
maintaining_VBG [PUBV]
a_DT
policy_NN
of_PIN
protecting_VBG
its_PIT
market_NN
position_NOMZ
by_PIN
the_DT
filing_NN
and_PHC
enforcement_NOMZ
of_PIN
patents_NN
and_PHC
trademarks_NN
,_,
Smith_NN
&_CC
Nephew_NN
has_VPRT
a_DT
policy_NN
of_PIN
opposing_VBG
third_JJ
party_NN
patents_NN
and_PHC
trademarks_NN
in_PIN
those_DEMO
areas_NN
that_TSUB
mightconflictwiththe_VPRT
Groups_NN
business_NOMZ
interests_NN
._.
In_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
its_PIT
business_NOMZ
,_,
the_DT
Group_NN
enters_VPRT
into_PIN
a_DT
number_NN
of_PIN
licensing_GER
arrangements_NOMZ
with_PIN
respect_NN
to_PIN
its_PIT
products_NN
._.
None_INPR
of_PIN
these_DEMO
arrangements_NOMZ
individually_RB
is_VPRT [PASS]
considered_VBN [PRIV]
material_NN
to_PIN
the_DT
operations_NOMZ
and_CC
the_DT
financial_JJ
results_NN
of_PIN
the_DT
Group_NN
._.
PROPERTY_NN
,_,
PLANT_NN
AND_PHC
EQUIPMENT_NOMZ
TheGroups_NN
as_IN
follows_VPRT
:_:
Approximate_JJ
area_NN
Square_NN
feet_NN
000s_CD
Group_NN
Head_NN
Office_NN
inLondon_NN
,_,
England_NN
..._:
..._:
..._:
..._:
..._:
..._:
..._:
..._:
..._:
..._:
15_CD
Group_NN
research_NN
facility_NOMZ
inYork_NN
,_,
England_NN
..._:
..._:
..._:
..._:
..._:
..._:
..._:
..._:
..._:
..._:
83_CD
Orthopaedics_NN
headquarters_NN
and_PHC
inMemphis_NN
,_,
Tennessee_NN
..._:
..._:
..._:
784_CD
Orthopaedics_NN
distributionfacility_NOMZ
inMemphis_NN
,_,
Tennessee_NN
..._:
..._:
..._:
..._:
..._:
..._:
..._:
102_CD
Orthopaedics_NN
inMemphis_NN
,_,
Tennessee_NN
..._:
..._:
..._:
..._:
..._:
..._:
._.
84_CD
inAndover_NN
,_,
Massachusetts_NN
..._:
..._:
..._:
..._:
..._:
..._:
..._:
._.
._.
112_CD
inMansfield_NN
,_,
Massachusetts_NN
..._:
..._:
..._:
..._:
..._:
..._:
98_CD
inOklahomaCity_NOMZ
,_,
Oklahoma_NN
..._:
..._:
..._:
..._:
..._:
..._:
100_CD
Advanced_NN
WoundManagement_NOMZ
headquarters_NN
and_PHC
inHull_NN
,_,
England_NN
..._:
..._:
546_CD
Advanced_NN
WoundManagement_NOMZ
inGilberdyke_NN
,_,
England_NN
..._:
..._:
..._:
._.
._.
269_CD
Advanced_NN
WoundManagement_NOMZ
inLargo_NN
,_,
Florida_NN
..._:
..._:
..._:
..._:
..._:
188_CD
The_DT
orthopaedic_JJ
headquarters_NN
and_PHC
manufacturing_GER
facilities_NOMZ
in_PIN
Memphis_NN
and_CC
the_DT
advanced_JJ
wound_NN
management_NOMZ
facilities_NOMZ
in_PIN
Hull_NN
,_,
Gilberdyke_NN
and_PHC
Largo_NN
are_VPRT [PASS]
freehold_VBN
while_OSUB
all_QUAN
other_JJ
leasehold_NN
._.
TheGroup_NN
has_VPRT [PEAS]
freehold_VBN
and_PHC
leasehold_VBN
interests_NN
in_PIN
real_JJ
estate_NN
in_PIN
other_JJ
countries_NN
throughout_PIN
the_DT
world_NN
,_,
but_CC
no_SYNE
other_JJ
is_VPRT [BEMA]
significant_JJ
individuallyto_NN
the_DT
Group_NN
._.
Whererequired_NN
,_,
the_DT
appropriate_JJ
governmental_JJ
authoritieshave_NN
approved_VBD
the_DT
facilities_NOMZ
._.
During_PIN
2005_CD
the_DT
Group_NN
announced_VBD [PUBV]
the_DT
closure_NN
of_PIN
two_CD
of_PIN
its_PIT
manufacturing_GER
locations_NOMZ
._.
The_DT
endoscopy_JJ
facility_NOMZ
in_PIN
Andover_NN
,_,
Massachusetts_NN
will_PRMD
be_VB [PASS]
closed_VBN
gradually_RB
during_PIN
2006_CD
and_CC
its_PIT
production_NOMZ
relocated_VBD
partly_DWNT
to_PIN
other_JJ
endoscopy_JJ
facilities_NOMZ
and_CC
partly_DWNT
out-sourced_JJ
to_PIN
third_JJ
party_NN
suppliers_NN
._.
Production_NOMZ
at_PIN
the_DT
advanced_JJ
wound_NN
management_NOMZ
facility_NOMZ
in_PIN
La_NN
Jolla_NN
,_,
California_NN
has_VPRT [PEAS]
ceased_VBN
following_VBG
the_DT
decision_NN
to_PIN
exit_NN
its_PIT
tissue_NN
engineering_GER
operations_NOMZ
and_CC
the_DT
facility_NOMZ
willbe_NN
closed_VBD
inthe_NN
first_JJ
quarter_NN
of_PIN
2006_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
rapid_JJ
rate_NN
of_PIN
sales_NN
growth_NN
in_PIN
recent_JJ
years_NN
and_CC
anticipated_VBN [PRIV]
continuing_VBG
strong_JJ
demand_NN
for_PIN
its_PIT
products_NN
,_,
the_DT
orthopaedics_NN
business_NOMZ
increased_VBD
its_PIT
manufacturing_GER
capacity_NOMZ
and_CC
administrative_JJ
facilities_NOMZ
in_PIN
2005_CD
in_PIN
line_NN
with_PIN
its_PIT
capacity_NOMZ
expansion_NN
plans_NN
._.
Additional_JJ
freehold_NN
manufacturing_VBG [WZPRES]
space_NN
of_PIN
104,000_CD
square_JJ
feet_NN
and_PHC
leasehold_NN
administrative_JJ
space_NN
of_PIN
84,000_CD
square_JJ
feet_NN
were_VBD
acquiredinMemphis_NN
._.
During_PIN
2005_CD
,_,
in_PIN
the_DT
UK_NN
,_,
new_JJ
leasehold_NN
facilities_NOMZ
for_PIN
the_DT
development_NOMZ
,_,
manufacture_NN
and_PHC
distribution_NOMZ
of_PIN
BHR_NN
products_NN
were_VBD [PASS]
acquired_VBN
in_PIN
the_DT
Warwick_NN
area_NN
and_CC
consolidated_JJ
with_PIN
the_DT
UK_NN
Orthopaedics_NN
operations_NOMZ
._.
The_DT
expansion_NN
in_PIN
the_DT
Groups_NN
facilities_NOMZ
did_VBD
not_XX0
and_CC
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
liquidity_NOMZ
and_PHC
resources_NN
._.
15_CD
LEGAL_NN
PROCEEDINGS_GER
The_DT
Company_NN
and_CC
its_PIT
subsidiaries_NN
are_VPRT
parties_NN
to_PIN
product_NN
liability_NOMZ
and_CC
various_JJ
legal_JJ
proceedings_GER
,_,
some_QUAN
of_PIN
which_WDT [PIRE]
include_VPRT
claims_NN
for_PIN
substantial_JJ
damages_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
considered_VBN [PRIV]
to_TO
constitute_VB
ordinary_JJ
and_PHC
routine_JJ
litigation_NOMZ
incidental_JJ
to_PIN
the_DT
businesses_NOMZ
conducted_VBN [WZPAST]
by_PIN
the_DT
Group_NN
._.
The_DT
outcome_NN
of_PIN
such_JJ
proceedings_GER
can_POMD
not_XX0
readily_RB
be_VB [PASS]
foreseen_VBN
,_,
but_CC
other_JJ
than_PIN
as_IN
detailed_JJ
below_PLACE
management_NOMZ
believes_VPRT [PRIV]
that_THVC
they_TPP3
will_PRMD
not_XX0
result_VB
in_PIN
any_QUAN
material_NN
adverse_JJ
effect_NN
onthe_NN
of_PIN
operations_NOMZ
of_PIN
the_DT
Group_NN
._.
In_PIN
August_NN
2003_CD
the_DT
Group_NN
withdrew_VBD
voluntarily_RB
from_PIN
all_QUAN
markets_NN
the_DT
macrotextured_JJ
versions_NN
of_PIN
its_PIT
OXINIUM_NN
femoral_JJ
knee_NN
components_NN
._.
As_IN
at_PIN
that_DEMO
date_NN
2,971_CD
components_NN
had_VBD [PEAS]
been_VBN [PASS]
implanted_VBN
of_PIN
which_WDT [PIRE]
approximately_RB
2,471_CD
were_VBD [BEMA]
in_PIN
the_DT
USA_NN
,_,
450_CD
in_PIN
Australia_NN
and_CC
50_CD
in_PIN
Europe_NN
,_,
the_DT
first_JJ
component_NN
having_VBG [WZPRES] [PEAS]
been_VBN [PASS]
implanted_VBN
in_PIN
December_NN
2001_CD
._.
The_DT
product_NN
was_VBD [PASS]
withdrawn_VBN
when_RB
management_NOMZ
became_VBD
aware_JJ
of_PIN
a_DT
higher_JJ
than_PIN
usual_JJ
percentage_NN
of_PIN
reports_NN
of_PIN
early_TIME
revisions_NN
revisions_NN
are_VPRT
implants_NN
which_WDT [WHSUB]
need_VPRT
to_TO
be_VB [PASS]
replaced_VBN
._.
It_PIT
appears_VPRT [SMP]
that_THVC
some_QUAN
patients_NN
do_VPRT
not_XX0
achieve_VB
adequate_JJ
initial_JJ
fixation_NOMZ
and_CC
that_DEMO
in_PIN
other_JJ
patients_NN
,_,
while_OSUB
there_EX
appears_VPRT [SMP]
to_TO
be_VB [BEMA]
good_JJ
initial_JJ
fixation_NOMZ
,_,
this_DEMP
does_VPRT
not_XX0
persevere_VB
._.
Smith_NN
&_CC
Nephew_NN
has_VPRT [SPAU] [PEAS]
extensively_RB
tested_VBN
and_PHC
investigated_VBN
the_DT
cause_NN
of_PIN
these_DEMO
early_TIME
revisions_NN
._.
A_DT
group_NN
of_PIN
medical_JJ
and_PHC
scientific_JJ
experts_NN
retained_VBN
and_PHC
managed_VBN
by_PIN
the_DT
Groups_NN
defense_NN
lawyers_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
finish_VB
its_PIT
workinthis_NN
regard_VPRT
inmid-2006_NN
._.
As_IN
at_PIN
31_CD
December_NN
2005_CD
955_CD
implants_NN
had_VBD [PEAS]
been_VBN [PASS]
revised_VBN
and_CC
settlements_NOMZ
agreed_VBD [SUAV] [PUBV]
with_PIN
patients_NN
in_PIN
respect_NN
of_PIN
771_CD
of_PIN
these_DEMO
revisions_NN
._.
The_DT
total_JJ
amount_NN
paid_VBN [WZPAST]
out_PIN
in_PIN
settlements_NOMZ
,_,
legal_JJ
costs_NN
and_CC
associated_VBN
expenses_NN
was_VBD [BEMA]
78m_CD
of_PIN
which_WDT [PIRE]
32m_NN
was_VBD [PASS]
recovered_VBN
from_PIN
the_DT
insurer_NN
that_TSUB
provides_VPRT
the_DT
primary_JJ
layer_NN
and_CC
65_CD
%_NN
of_PIN
the_DT
first_JJ
excess_JJ
layer_NN
in_PIN
the_DT
Groups_NN
global_JJ
product_NN
liability_NOMZ
program_NN
._.
The_DT
balance_NN
of_PIN
46m_CD
is_VPRT [BEMA]
due_PRED
from_PIN
insurers_NN
in_PIN
respect_NN
of_PIN
the_DT
remainderof_JJ
the_DT
first_JJ
excess_JJ
layer_NN
and_CC
the_DT
second_JJ
excess_JJ
layer_NN
._.
In_PIN
December_NN
2004_CD
the_DT
Group_NN
was_VBD [PASS]
notified_VBN
that_DEMO
two_CD
insurance_NN
carriers_NN
who_WP [WHSUB]
comprise_VPRT
35_CD
%_NN
of_PIN
the_DT
first_JJ
and_CC
80_CD
%_NN
of_PIN
the_DT
second_JJ
excess_JJ
layers_NN
of_PIN
the_DT
Groups_NN
global_JJ
product_NN
liability_NOMZ
program_NN
had_VBD [PEAS]
declined_VBN
coverage_NN
for_PIN
macrotextured_JJ
claims_NN
due_JJ
to_PIN
differences_NN
in_PIN
the_DT
interpretation_NOMZ
of_PIN
the_DT
policy_NN
wording_GER
._.
In_PIN
December_NN
2005_CD
the_DT
other_JJ
insurance_NN
carrier_NN
with_PIN
a_DT
20_CD
%_NN
participation_NOMZ
in_PIN
the_DT
second_JJ
excess_JJ
layer_NN
declined_VBD
coverage_NN
._.
Management_NOMZ
intends_VPRT [SUAV]
to_TO
take_VB
all_QUAN
steps_NN
available_JJ
to_PIN
it_PIT
in_PIN
order_NN
to_TO
enforce_VB
this_DEMO
coverage_NN
._.
A_DT
charge_NN
of_PIN
80m_CD
representing_VBG
the_DT
amount_NN
outstanding_JJ
from_PIN
these_DEMO
insurers_NN
and_CC
an_DT
estimate_NN
of_PIN
the_DT
cost_NN
associated_VBN [WZPAST]
with_PIN
claims_NN
likely_JJ
to_TO
arise_VB
in_PIN
the_DT
future_JJ
assuming_VBG [PRIV]
that_THVC
insurance_NN
cover_NN
continues_VPRT
to_TO
be_VB [BEMA]
unavailable_PRED
from_PIN
these_DEMP
and_CC
subsequent_JJ
excess_JJ
layer_NN
insurers_NN
was_VBD [PASS]
recorded_VBN
in_PIN
2004_CD
._.
Apart_RB
from_PIN
the_DT
impact_NN
of_PIN
translational_JJ
exchange_NN
rate_NN
movements_NOMZ
there_RB
has_VPRT [PEAS]
been_VBN [BEMA]
no_SYNE
changeto_NN
the_DT
estimated_VBN [PRIV]
liabilityduring2005_NN
._.
The_DT
charge_NN
was_VBD [PASS]
calculated_VBN [PRIV]
based_VBN
on_PIN
:_:
1_LS
the_DT
amount_NN
outstanding_JJ
at_PIN
31_CD
December_NN
2004_CD
from_PIN
the_DT
insurers_NN
who_WP [WHSUB]
declined_VBD
coverage_NN
:_:
2_CD
an_DT
estimate_NN
of_PIN
the_DT
average_JJ
cost_NN
in_PIN
respect_NN
of_PIN
revisions_NN
where_RB
claims_NN
were_VBD [BEMA]
unresolved_PRED
at_PIN
that_DEMO
date_NN
:_:
and_ANDC
3_CD
an_DT
estimate_NN
of_PIN
the_DT
number_NN
of_PIN
settlements_NOMZ
of_PIN
future_JJ
revisions_NN
based_VBN [WZPAST]
on_PIN
the_DT
current_JJ
trend_NN
and_CC
decaying_VBG
to_PIN
zero_CD
after_IN
five_CD
years_NN
and_CC
an_DT
estimation_NOMZ
of_PIN
the_DT
average_JJ
future_JJ
cost_NN
per_PIN
settlement_NOMZ
._.
The_DT
amount_NN
of_PIN
provision_NN
remaining_VBG [WZPRES]
at_PIN
31_CD
December_NN
2005_CD
to_TO
cover_VB
pending_VBG
claims_NN
and_PHC
claims_NN
in_PIN
respect_NN
of_PIN
future_JJ
revisions_NN
,_,
assuming_VBG [PRIV]
noinsurancecoveris_NN
available_JJ
,_,
was_VBD [BEMA]
44m_CD
,_,
whichmanagement_NOMZ
believes_VPRT [PRIV]
is_VPRT [BEMA]
adequate_PRED
._.
As_IN
at_PIN
24_CD
February_NN
2006_CD
,_,
964_CD
implants_NN
had_VBD [PEAS]
been_VBN [PASS]
revised_VBN
and_CC
settlements_NOMZ
agreed_VBD [SUAV] [PUBV]
with_PIN
patients_NN
in_PIN
respect_NN
of_PIN
796_CD
of_PIN
these_DEMO
revisions_NN
._.
The_DT
Groups_NN
assessment_NOMZ
of_PIN
the_DT
impact_NN
of_PIN
these_DEMO
revisions_NN
and_CC
related_VBN
matters_NN
constitute_VPRT
forward_RB
looking_VBG
statements_NOMZ
that_TSUB
are_VPRT [BEMA]
subject_PRED
to_PIN
uncertainties_NN
,_,
including_VBG
uncertainties_NN
relating_VBG [WZPRES]
to_PIN
the_DT
outcome_NN
of_PIN
settlements_NOMZ
as_IN
compared_VBN
to_PIN
the_DT
assumptions_NOMZ
made_VBN [WZPAST]
in_PIN
estimating_VBG [PRIV]
claim_NN
amounts_NN
._.
Smith_NN
&_CC
Nephew_NN
can_POMD
not_XX0
provide_VB
assurance_NN
that_TOBJ
these_DEMO
estimates_NN
will_PRMD
prove_VB [PRIV]
correct_JJ
._.
Depending_VBG [PRESP]
on_PIN
the_DT
number_NN
and_CC
average_JJ
cost_NN
of_PIN
future_JJ
settlements_NOMZ
,_,
costs_NN
may_POMD
be_VB [BEMA]
greater_JJ
orless_JJ
than_PIN
the_DT
amountprovided_JJ
see_VPRT [PRIV]
Risk_NN
Factors_NN
._.
In_PIN
March_NN
2005_CD
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Newark_NN
,_,
New_NN
Jersey_NN
issued_VBD
a_DT
subpoena_NN
to_PIN
the_DT
Groups_NN
orthopaedic_JJ
business_NOMZ
asking_VBG [SUAV] [WZPRES]
for_PIN
copies_NN
of_PIN
its_PIT
consulting_GER
,_,
professional_JJ
service_NN
and_PHC
remuneration_NOMZ
agreements_NOMZ
with_PIN
orthopaedic_JJ
reconstructive_JJ
surgeons_NN
._.
Four_CD
of_PIN
the_DT
divisions_NN
major_JJ
competitors_NN
received_VBD
similar_JJ
subpoenas_NN
._.
The_DT
Company_NN
is_VPRT [BEMA]
co-operating_JJ
fully_AMP
with_PIN
the_DT
US_FPP1
Attorney_NN
,_,
has_VPRT [PEAS]
provided_VBN
copies_NN
of_PIN
the_DT
requested_VBN [SUAV]
contracts_NN
and_CC
is_VPRT
gathering_VBG [PRIV]
additional_JJ
documentswhichhave_NN
also_RB
been_VBN [PASS]
requested_VBN [SUAV]
._.
